Strober W, Lúdvíksson B R, Fuss I J
Ann Intern Med. 1998 May 15;128(10):848-56. doi: 10.7326/0003-4819-128-10-199805150-00009.
In recent years, it has become apparent that overproduction of the Th1 cytokines interleukin-12 and interferon-gamma is the probable driving force behind murine models of intestinal inflammation resembling Crohn disease and intestinal inflammation in humans with Crohn disease. In addition, studies of murine models strongly suggest that this overproduction is associated with inadequate secretion of the counter-regulatory and anti-inflammatory cytokine transforming growth factor-beta. Thus, mucosal inflammation in models (and possibly in humans) may result from an imbalance between normally occurring positive (immunogenic or inflammatory) responses and negative (tolerogenic or anti-inflammatory) mucosal immune responses. These new findings and the hypotheses that arise from them are being used to construct new approaches to the treatment of Crohn disease that are based on the administration of anti-inflammatory cytokines and anti-cytokine antibodies.
近年来,有一点已变得很明显,即Th1细胞因子白细胞介素-12和干扰素-γ的过度产生可能是类似于克罗恩病的小鼠肠道炎症模型以及患有克罗恩病的人类肠道炎症背后的驱动因素。此外,对小鼠模型的研究有力地表明,这种过度产生与反调节和抗炎细胞因子转化生长因子-β的分泌不足有关。因此,模型(可能还有人类)中的黏膜炎症可能是由正常发生的正向(免疫原性或炎症性)反应与负向(耐受性或抗炎性)黏膜免疫反应之间的失衡所致。这些新发现以及由此产生的假说正被用于构建基于给予抗炎细胞因子和抗细胞因子抗体的克罗恩病治疗新方法。